Antiplatelet drugs in cardiovascular prevention: stroke prevention in patients with thrombogenic heart disease.
(1) In patients with atrial fibrillation and a moderate embolic risk, aspirin reduces the risk of stroke and has a comparable risk-benefit ratio to oral anticoagulants.  (2) Oral anticoagulants are superior to aspirin in patients with atrial fibrillation and a history of stroke. (3) In patients with a mechanical valve prosthesis and a high embolic risk, the oral anticoagulant + aspirin combination has a better risk-benefit ratio than oral anticoagulant alone.
D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004617:Embolism / Q000517:prevention & control; D006350:Heart Valve Prosthesis; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin